UCLA algorithm nearly matches experienced radiologists in prostate cancer detection

Researchers from the University of California, Los Angeles, have developed an artificial neural network capable of identifying and diagnosing prostate cancer almost as well as radiologists with a decade of experience.

The system, FocalNet, finds and predicts the aggressiveness of cancers by evaluating MRIs, much like radiologists. Unlike radiologists, it does that by using an algorithm that comprises more than a million trainable variables.

“Multiparametric MRI (mp-MRI) is considered the best noninvasive imaging modality for diagnosing prostate cancer,” first author Ruiming Cao and colleagues wrote in IEEE Transactions on Medical Imaging. “However, mp-MRI for prostate cancer diagnosis is currently limited by the qualitative or semi-qualitative interpretation criteria, leading to inter-reader variability and a suboptimal ability to assess lesion aggressiveness.

“Convolutional neural networks are a powerful method to automatically learn the discriminative features for various text tasks, including cancer detection.”

The team at UCLA trained FocalNet by feeding it scans from 417 men with prostate cancer. The algorithm was asked to analyze the images, filing away the information it learned to better assess and classify tumors in the future. In testing against experienced radiologists who analyzed the same images, FocalNet achieved an accuracy of 80.5%—just below the radiologists’ 83.9%.

Cao et al. said their research suggests an AI system like FocalNet could save time in cancer diagnosis and might serve as a tool to provide diagnostic guidance to radiologists with less real-world experience.

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.